key: cord-0736070-kjtyh8it
authors: Pannu, Jessie; Ciotti, Susan; Ganesan, Shyamala; Arida, George; Costley, Chad; Fattom, Ali
title: Nanodroplet-Benzalkonium Chloride Formulation Demonstrates In Vitro and Ex-Vivo Broad-Spectrum Antiviral Activity Against SARS-CoV-2 and other Enveloped Viruses
date: 2020-11-12
journal: bioRxiv
DOI: 10.1101/2020.11.12.377598
sha: 766d130c34743ce2c0eb6304bf3ed06c38784906
doc_id: 736070
cord_uid: kjtyh8it

The Covid-19 pandemic has highlighted the importance of aerosolized droplets inhaled into the nose in the transmission of respiratory viral disease. Inactivating pathogenic viruses at the nasal portal of entry may reduce viral loads, thereby reducing transmission and contagion. We have developed an oil-in-water nanoemulsion (nanodroplet) formulation containing the potent antiseptic 0.13% Benzalkonium Chloride (NE-BZK) which demonstrates safe and broad anti-viral activity. While The Centers for Disease Control and Prevention (CDC) have reported that BZK may have less reliable activity than ethyl alcohol against certain viruses, including coronaviruses, we have demonstrated that NE-BZK exhibits broad-spectrum, long-lasting antiviral activity with >99.99% in vitro killing of enveloped viruses including SARS-CoV-2, human coronavirus, RSV and influenza B. Furthermore, in vitro studies demonstrated that NE-BZK continues to kill >99.99% of human coronavirus even when diluted 20-fold, while 0.13% aqueous BZK solution (AQ-BZK) did not. Ex vivo studies of NE-BZK on human cadaver skin demonstrated persistent >99.99% killing of human coronavirus for at least 8 hours after application. AQ-BZK failed to demonstrate durable antimicrobial activity on skin over time. The repeated application of NE-BZK, twice daily for 2 weeks on to rabbit nostrils indicated safety with no irritation. These findings demonstrate that formulating BZK on the surface of proprietary nanodroplets offers a safe and effective antiviral as a significant addition to strategies to combat the spread of respiratory viral infectious diseases.

The nasal cavity is a primary route of entry for respiratory pathogens. Recently published studies 42 on SARS-CoV-2 highlight the prominent role of nasal epithelium in initial infection, viral 43 replication, and transmission. [1] [2] [3] Other highly contagious and pathogenic viruses such as influenza, 44 respiratory syncytial virus (RSV) and human coronavirus also enter through the nasal mucosa, The CDC has reported varied antiviral activity of the widely used skin antiseptic AQ-BZK, 52 including that it can be ineffective against coronavirus. 9,10 NE-BZK is a proprietary antiseptic 53 which incorporates the active ingredient benzalkonium chloride (0.13% BZK) in oil-in-water 54 nanodroplets. The nanodroplets are approximately 350 nm in size and have positively charged 55 surfaces. Given their size, they persist following application for up to 24 hours in hair follicles, 56 sweat glands and sebaceous glands which can harbor pathogens. 11 While these nanodroplets are 57 small enough to penetrate these glands of the skin, they are too large to penetrate through the 58 epidermis and are therefore not absorbed systemically. With positively charged surfaces, the 59 nanodroplets repel each other which prevents the nanodroplets from coalescing and keeps the 60 active ingredient BZK from inactivating through crystallization. 12 The surface of enveloped 61 viruses (e.g. SARS-CoV-2, influenza, RSV) are negatively charged. 13 Therefore, the positively 62 charged nanodroplets in NE-BZK are attracted to these viruses, delivering the antiseptic payload 63 4 directly to the surface of the pathogen where splitting and killing occurs. Ethyl alcohol products 64 comprise over 80% of skin sanitizers available in the U.S. and have been promoted by the CDC as 65 preferred for infection risk reduction. 9,14 However, alcohol and water evaporate quickly after 66 application, leading to short duration of action. Similarly, in the case of widely available aqueous 

Our experience in this field predicts that formulating cationic surfactants such as BZK in the 80 nanoemulsion (nanodroplets) enhances its antiviral activity. Since the well-known antiseptic BZK 81 in standard aqueous solutions has demonstrated varied activity against viruses and bacteria, 82 including human coronavirus, we formulated BZK in oil-in-water nanodroplets. We evaluated the 83 broad-spectrum antiviral activity of NE-BZK against various enveloped respiratory viruses. Data 84 presented in Figure 1 shows that NE-BZK inactivated >99.99% of all tested enveloped viruses, 85 including SARS-CoV-2. The inactivation of these viruses was achieved within 5 minutes of 86 5 mixing with the nanoemulsion, indicating that the NE-BZK nanodroplets efficiently delivered the 87 BZK to the enveloped viral particles where inactivation occurs.

The results of these studies demonstrate that NE-BZK has sustained broad-spectrum antiviral 89 activity against multiple respiratory pathogens, including SARS-CoV-2, Influenza B, and RSV. following 5 minutes exposure was evaluated. Data presented in Table 2 demonstrate that even at 98 highest tested dilution of 1/20, the NE-BZK formulation continued to demonstrate >99.99% killing 99 while aqueous AQ-BZK antiviral activity was diminished with dilutions.

Following demonstration of in vitro activity against human coronavirus, an ex-vivo time-kill study 102 was performed following pre-treatment of human cadaver skin with NE-BZK (0.13% BZK) or 103 AQ-BZK for 4 and 8 hours. As presented in Table 3 , NE-BZK achieved >4.7 log killing of HCoV 104 229E at both the 4-and 8-hour time points, while AQ-BZK exhibited only 1.5 log killing at 4 hours 105 and no detectable activity at 8 hours. These data suggest that NE-BZK could maintain its antiviral 106 activity for a longer time due to stability of this formulation compared to AQ-BZK formulations. intranasal swabbing was applied. The NE-BZK was applied to the inner nostril and nasal mucosa 227 using a puritan foam tip. Care was taken that swab was applied thoroughly in ten circular motions. Table 1 . 20

The serum samples collected at two hours and two days post NE-BZK application was analyzed 235 using qualified reverse phase HPLC method. The samples were extracted with three parts of 236 acetonitrile and filtered using 0.2µm low protein binding PTFE filter before injecting into column.

The samples were run on Phenomenex Luna 5µ column, using 0.04M Sodium acetate in 238 acetonitrile as mobile phase. The samples were run at a flow rate of 2mL/ minute with 100µL 239 injection volume. The peaks were detected using 254nm wavelength. The analytical assay 240 detection limit was 0.094µg/mL. Down facility, Salisbury SP4 0JG United Kingdom. We thank Sue Charlton for her excellent 255 technical assistance in running the SARS-Cov-2 in vitro experiments at PHE. 256 We are thankful to Lakshman Caldera from BlueWilow Biologics for analyzing the serum samples 257 from rabbit study. All of the authors whose names are listed are employees of BlueWillow Severe, pronounced swelling, raised border (>1mm) Limit of detection (LOD) = 1

Temporal dynamics in viral shedding and transmissibility 264 of COVID-19

SARS-CoV-2 viral load in upper respiratory specimens 266 of infected patients

Detection of SARS-CoV-2 in 268 different types of clinical specimens

Influenza A viruses are transmitted 270 via the air from the nasal respiratory epithelium of ferrets

Risk of primary infection and reinfection 272 with respiratory syncytial virus

The effects of coronavirus on human 274 nasal ciliated respiratory epithelium

Virological assessment of hospitalized patients 278 with COVID-2019

Influenza A viruses are transmitted via the air from the nasal 281 respiratory epithelium of ferrets

CDC Guidance document on Hand Hygiene recommendations-Guidance for Healthcare 283 Providers about Hand Hygiene and COVID 19

The action of three antiseptics/disinfectants against enveloped and 285 non-enveloped viruses

Novel Nanoemulsion NB-001 permeates skin by 287 the follicular route

Abstract A-1898

Antimicrobial activity of chlorhexidine diacetate and 291 benzalkonium chloride against Pseudomonas aeruginosa and its response to biocide residues

The interaction between respiratory 294 pathogens and mucus

Guideline for Hand Hygiene in Health-Care Settings Recommendations of the Healthcare 296

Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand 297

Hygiene Task Force

Poloxamer hydrogels for biomedical applications

Pre-303 clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine

Standard Test method to assess the activity of microbicides against viruses 306 in suspension

Titration of human coronaviruses, HCoV-308 229E and HCoV-OC43, by an indirect immunoperoxidase assay

Percutaneous absorption: on the relevance of in vitro data

Methods for the Study of Irritation and Toxicity 314 of Substances Applied Topically to the Skin and Mucous Membranes

Reveals a Variable Infection Gradient in the Respiratory Tract

Lessler 325 J. 2020. The Incubation Period of Coronavirus Disease

Reported Confirmed Cases: Estimation and Application

SARS-CoV-2 viral load predicts COVID-19 331 mortality

In Vitro 333 Efficacy of a Povidone-Iodine Nasal Antiseptic for Rapid Inactivation

Safety and immunogenicity of a novel nanoemulsion mucosal 337 adjuvant W805EC combined with approved seasonal influenza antigens

NB-001 Study Group. Treatment with a novel topical nanoemulsion (NB-341 001) speeds time to healing of recurrent cold sores

Survival of SARS-CoV-2 and influenza 344 virus on the human skin: Importance of hand hygiene in COVID-19